Ask AI
ProCE Banner Activity

Smarter. Stronger. Together. Optimizing MDS Care and Addressing Health Disparities Through Education of Providers, Patients, and Caregivers

Slideset

Slides from Amer Zeidan, MBBS, highlighting some of the most important developments in optimizing the management of myelodysplastic syndromes, including patient survey results, clinical trial findings and their implications for clinical practice

Released: November 22, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options LLC, in partnership with The Myelodysplastic Syndromes Foundation, Inc.

ProCE Banner

Supporters

Supported by an educational grant from AbbVie Inc., Geron and Karyopharm Therapeutics.

AbbVie Inc.

Geron

Karyopharm Therapeutics

Partners

MDS Foundation

ProCE Banner

Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology, Clinical Trails Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Hematology, Department of Internal Medicine, Yale School of Medicine
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: consultant/advisor/speaker/clinical trial committee: AbbVie, Akeso, Agios, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, FibroGen, Glycomimetics, Genentech, Gilead, Geron, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Takeda, Treadwell, Taiho, Vincerx, Zentalis.